Related by context. All words. (Click for frequent words.) 74 Annamycin 69 relapsed leukemia 69 Atiprimod 69 IMiDs R 67 PI3K/Akt pathway inhibitor 67 phase IIb clinical 67 investigational monoclonal antibody 67 non nucleoside inhibitor 67 JAK inhibitor 67 docetaxel Taxotere R 67 PNP inhibitor 67 sapacitabine CYC# 66 immunotherapeutic agent 66 relapsed multiple myeloma 66 Panzem R 66 Acute Myeloid Leukemia AML 66 Cloretazine 66 Archexin 66 alvespimycin 66 seliciclib CYC# 66 Phase #b/#a clinical 66 drug pipeline TAFA# 66 FOLOTYN ® 66 IMiDs ® 66 Omacetaxine 65 Troxatyl 65 Sym# 65 AEG# 65 receptor tyrosine kinase inhibitor 65 targeted radiotherapeutic 65 OMP #R# 65 phase IIa clinical 65 Voreloxin 65 Quinamed 65 Nexavar ® 65 liposomal formulation 65 R#/MEM # 65 IAP inhibitors 65 metaglidasen 65 proteasome inhibitor 65 Personalized Immunotherapy 65 TBC# 65 Azedra 65 ENMD # 65 nucleoside analog 65 2 methoxyestradiol 65 IMiDs ® compound 65 huC# DM4 65 PDE4 inhibitor 65 selective kinase inhibitor 65 orally administered inhibitor 65 Daclizumab 65 BRIM2 65 MKC# MKC# PP 65 XL# anticancer compounds 65 candidate REP# 65 oral prodrug 65 Amrubicin 64 BAY #-# 64 Dapagliflozin 64 PEG SN# 64 acyclovir Lauriad R 64 Elagolix 64 Curaxin 64 PKC# 64 mertansine 64 INCB# [001] 64 Blinatumomab 64 elotuzumab 64 radiation sensitizer 64 lintuzumab SGN 64 Angiocept 64 volociximab 64 CB2 selective receptor agonist 64 VEGFR2 inhibitor 64 Glufosfamide 64 CYC# 64 refractory chronic lymphocytic 64 orally bioavailable 64 imatinib Gleevec ® 64 PDX pralatrexate 64 Proxinium TM 64 Elotuzumab 64 evaluating tivozanib 64 investigational humanized monoclonal antibody 64 trastuzumab DM1 T DM1 64 YONDELIS 64 novel immunomodulatory 64 Epratuzumab 64 telomerase therapeutic 64 Alocrest 64 Aplidin R 64 IMC A# 64 triggers apoptosis programmed 64 TKB# 64 reslizumab 63 Mipomersen 63 HuLuc# 63 histone deacetylase HDAC inhibitor 63 rALLy clinical trial 63 oncolytic virus therapies 63 PORxin TM 63 anticancer compound 63 dasatinib Sprycel ® 63 PD LID 63 selective androgen receptor modulator 63 forodesine hydrochloride 63 OMP #M# 63 OncoVEX GM CSF 63 IAP inhibitor 63 Pimavanserin 63 oral proteasome inhibitor 63 IL# PE#QQR 63 PSMA ADC 63 Peginterferon alfa 2b 63 R sorafenib tablets 63 CD# monoclonal antibody 63 PrevOnco 63 Panzem R NCD 63 AQ4N 63 oral Factor Xa 63 Allovectin 7 63 humanized anti 63 PSN# [002] 63 LHRH antagonist 63 CEQ# 63 HQK 63 highly selective endothelin 63 familial amyloidotic polyneuropathy FAP 63 mitogen activated ERK kinase 63 MEK inhibitors 63 leukemia AML 63 humanized monoclonal antibody 63 Kit CD# positive 63 Phase Ib clinical 63 Pradefovir 63 ZK EPO 63 Phase Ib II 63 Ridaforolimus 63 RH1 63 BiovaxID TM 63 Carfilzomib 63 virus HCV protease inhibitor 63 AKT inhibitor 63 novel peptide 63 ALN TTR# 63 Hsp# Inhibitor 63 mTOR inhibitor 63 MKC# MT 63 Symadex 63 Cannabinor 63 leading oral taxane 63 Vidaza R 63 Onco TCS 62 Pertuzumab 62 investigational pan BCR 62 Alfacell proprietary ribonuclease 62 JAK inhibitors 62 Bezielle 62 targeted antifolate 62 IMA# 62 XL# XL# 62 pan HDAC inhibitor 62 Cloretazine ® 62 Nanobody 62 CDP# 62 entinostat 62 hypoxia activated prodrug 62 ocular formulation 62 Dasatinib 62 HIV maturation inhibition 62 erlotinib Tarceva R 62 Seliciclib 62 Maribavir 62 Vitaxin 62 Solazed TM 62 Factor VIIa 62 MT# MEDI 62 TRACON Pharmaceuticals 62 SinuNase TM 62 epothilones 62 Perifosine 62 phase III isavuconazole 62 sorafenib tablets 62 relapsed refractory multiple myeloma 62 Zolinza 62 HIV integrase inhibitor 62 HGS ETR1 62 Luteinizing Hormone Releasing Hormone 62 Sapacitabine 62 evaluating satraplatin 62 HGS# 62 metastatic hormone refractory 62 NXL# 62 OvaRex ® MAb 62 Aflibercept 62 multi kinase inhibitor 62 Vicriviroc 62 Curaxin CBLC# 62 CD4 monoclonal antibody 62 Xanafide 62 initiated Phase Ib 62 CYT# potent vascular disrupting 62 IRX 2 62 TRAIL receptor antibodies 62 demonstrated antitumor activity 62 TELINTRA 62 Laquinimod 62 IMPDH inhibitor 62 IgG1 monoclonal antibody 62 Phase Ib clinical trials 62 Pazopanib 62 CYT# vascular disrupting 62 INSPIRE Trial Phase III 62 apricitabine ATC 62 non nucleoside HCV 62 erlotinib Tarceva ® 62 selective immunoproteasome inhibitor 62 Phase IIa clinical 62 BZL# 62 cutaneous T cell 62 Tesetaxel 62 platinum chemotherapeutic 62 melanocortin receptor agonists 62 ABL inhibitor 62 oral ghrelin agonist 62 class mGluR5 inhibitor 62 antisense drug 62 EOquin 62 VitiGam 62 BCR ABL inhibitors 62 personalized cellular immunotherapy 62 hypoxia selective 62 immunosuppressive compound 62 Clofarabine 62 Evoltra ® 62 Guanilib 62 Panzem 62 RGB # 62 Ceflatonin R 62 orally dosed 62 docetaxel Taxotere ® 62 IMiDs 62 Azedra TM 62 generation URAT1 inhibitor 62 castrate resistant prostate cancer 61 CD# CEA 61 HGS ETR1 mapatumumab 61 KRN# 61 TRIOLEX ™ 61 HDAC Inhibitor 61 Akt inhibitor 61 Miraxion Amarin lead 61 sodium Injection 61 Ozarelix 61 rxRNA 61 vinca alkaloid 61 MGCD# [001] 61 XL# XL# XL# 61 Talabostat 61 XL# XL# XL# XL# 61 Aurora kinase inhibitor 61 Romidepsin 61 PRTX 61 Marqibo TM 61 pertuzumab 61 Phase IIa trials 61 lintuzumab 61 Onconase 61 MLN# 61 Aplidin 61 vascular disrupting agent 61 Linaclotide 61 dextromethorphan quinidine 61 lenalidomide Revlimid R 61 PRT# 61 accumulate preferentially 61 SinuNase ™ 61 HCV protease inhibitor 61 unique alkylating agent 61 Tyrima 61 hypereosinophilic syndrome 61 LymphoStat B belimumab 61 Phase #/#a trial 61 small molecule chemotherapeutic 61 MCSP respectively 61 Genasense ® oblimersen 61 registrational trial 61 subcutaneous formulation 61 Tarvacin TM 61 depsipeptide 61 PGL# 61 signal transduction inhibitor 61 Dacogen injection 61 peptibody 61 Insegia 61 AP# [003] 61 sodium glucose cotransporter 61 Cerimon 61 ProLindac TM 61 Ophthotech 61 Intravenous CP 61 relapsed MM 61 deforolimus 61 pseudobulbar affect PBA 61 Cloretazine R VNP#M 61 relapsed acute lymphoblastic 61 HepeX B TM 61 CCX# 61 Silodosin 61 HCD# [002] 61 sunitinib malate 61 PARP inhibitor 61 cell lymphoma CTCL 61 investigational immunotherapy 61 polymerase inhibitor 61 mapatumumab 61 tubulin inhibitor 61 LEUKINE 61 Hedgehog Pathway Inhibitor 61 dextofisopam 61 Myocet 61 class anticancer quinolone 61 Albugon 61 MEK inhibitor 61 oral nucleoside analogue 61 CBLC# 61 inhaled formulation 61 nucleoside analogue 61 Epothilones 61 ionotropic glutamate receptor antagonists 61 huN# DM1 61 PANVAC VF 61 phase IIb trial 61 CD3 monoclonal antibody 61 CCR5 antagonist 61 Initiates Enrollment 61 metastatic castration resistant 61 Pathway Inhibitor 61 bevacizumab Avastin ® 61 Phase IIb Trial 61 Bayer HealthCare Onyx Pharmaceuticals 61 Ofatumumab 61 INxin TM 61 molecular imaging radiopharmaceutical 61 APEX PD 61 CCR9 antagonist 61 MKC# 61 ATRA IV 61 StemEx 61 novel VDA molecule 61 SPRYCEL ® 61 Cetrorelix 60 Oral NKTR 60 Phase 2a clinical 60 LymphoStat B TM 60 RhuDex ® 60 leukemia CLL 60 TRC# 60 Phase 2b clinical trials 60 UPLYSO 60 Ferumoxytol 60 cutaneous T 60 cetuximab Erbitux R 60 PLK1 SNALP 60 AAG geldanamycin analog 60 oral dihydropyrimidine dehydrogenase DPD 60 delta opioid receptor 60 Clevudine 60 SAR# [004] 60 compound INCB# 60 HSP# inhibitor 60 Marqibo 60 Phase 2a Clinical Trial 60 chronic eosinophilic leukemia 60 R roscovitine 60 GW# [003] 60 Phase Ib IIa 60 Ostabolin C TM 60 nilotinib Tasigna ® 60 delivers fluocinolone acetonide FA 60 MAGE A3 ASCI 60 ganetespib 60 multicenter Phase II 60 pegylated liposomal doxorubicin 60 Initiates Phase II 60 alemtuzumab Campath 60 PXD# 60 Vidofludimus 60 DOS# 60 pralatrexate injection folate analogue 60 refractory AML 60 Gleevec resistant 60 DU #b 60 investigational protease inhibitor 60 delivery polymer matrix 60 blinded randomized placebo controlled 60 oral antiviral 60 HGS ETR2 60 Accelerated Intelligent 60 Phase IIIb clinical 60 Phase 1b clinical trials 60 IMC #B 60 JAK1 60 cathepsin K inhibitor 60 candidate CRLX# 60 ALS #-# 60 sorafenib Nexavar 60 TPI ASM8 60 Nexavar sorafenib 60 tiapamil 60 paclitaxel Taxol ® 60 SUPPRELIN R LA 60 Augment TM 60 Civacir 60 Campath ® 60 targeting CD# 60 Tarceva TM 60 angiogenesis inhibitor 60 ELACYT 60 small molecule glucokinase 60 lomitapide 60 Vandetanib 60 aggressive systemic mastocytosis 60 HER2 positive metastatic breast 60 WX UK1 60 Pralatrexate 60 Neulasta R 60 GRN#L 60 LAF# 60 rNAPc2 60 OXi# 60 KNS # 60 ThermoDox R 60 Atripla combines 60 Aryplase 60 Lisofylline LSF 60 PORxin TM platforms 60 Gemzar ® 60 MT#/MEDI-# 60 CR# vcMMAE 60 Phase 1b clinical 60 GLPG# 60 vemurafenib 60 diabetic neuropathic pain 60 vosaroxin 60 oral picoplatin 60 proteasome inhibitors 60 Dalbavancin 60 immunotherapeutic 60 Iluvien ® 60 oral talactoferrin 60 Phase Ib study 60 Aganocide 60 Tovaxin TM 60 Phase 2b Clinical Trial 60 Safinamide 60 CD# antibody [001] 60 histone deacetylase HDAC inhibitors 60 Phase 1a clinical 60 essential thrombocythemia ET 60 peripherally acting 60 Pharmos proprietary 60 TYZEKA 60 memantine HCl 60 CDK cyclin dependent 60 sorafenib Nexavar ® 60 ceftazidime 60 Pegloticase 60 rhIGF-I/rhIGFBP-3 60 Randomized Phase 60 Onalta 60 gefitinib Iressa 60 Fx #A 60 Completes Patient Enrollment 60 small molecule Hedgehog 60 PrevOnco ™ 60 talactoferrin 60 Plicera 60 refractory acute myeloid 60 compound PMX # 60 tramiprosate Alzhemed TM 60 ospemifene 60 forodesine 59 Vidaza ® 59 anti EGFR antibody 59 refractory gout 59 Cyclooxygenase Inhibiting Nitric Oxide 59 delafloxacin 59 Triapine 59 Presents Preclinical Data 59 PEGylated Fab fragment 59 systemic juvenile idiopathic 59 XYOTAX TM 59 polysaccharide polymer 59 midstage trials 59 Vicinium TM 59 renin inhibitor 59 cancer immunotherapies 59 Taxanes 59 Initiates Clinical 59 OncoVex 59 epothilone 59 PEP# [003] 59 Exherin 59 CTAP# Capsules 59 Pirfenidone 59 Telintra 59 Nexavar sorafenib tablets 59 selective S#P# receptor agonist 59 Pruvel TM 59 Zalypsis 59 RenaZorb TM 59 Phase Ib 59 Myolimus 59 Phase IIa trial 59 EZN 59 novel DACH platinum 59 oncolytic 59 cannabinor 59 TELCYTA 59 ADP receptor antagonist 59 galiximab 59 GV# [001] 59 investigational drug 59 advanced metastatic renal 59 targets Galectin receptors 59 Traficet EN 59 investigational oral 59 pediatric acute lymphoblastic 59 Adnectin 59 protein kinase inhibitor 59 intranasal formulation 59 Xcytrin R 59 HCV polymerase 59 include PLX IBD 59 generation PNP inhibitor 59 Olaparib 59 Nimotuzumab 59 Androxal TM 59 MYDICAR ® 59 Tumour Vascular Disrupting Agent 59 MultiStem ® 59 Mersana 59 ZEVALIN ® 59 clinical trials dacetuzumab SGN 59 generation purine nucleoside 59 Bortezomib 59 protein kinase inhibitors 59 Zorbtive TM 59 ApoB SNALP 59 ASONEP TM 59 candidate Zenvia 59 Fludara ® 59 Phase IIb clinical trials 59 telomerase inhibitor drug 59 Phase 2b clinical 59 multicenter Phase III 59 Zenvia ™ 59 TG# [003] 59 urocortin 2 59 GSK '# 59 Receives Orphan Drug Designation 59 BCG refractory carcinoma 59 vaccine GRNVAC1 59 Genasense ® 59 VELCADE melphalan 59 relapsed acute lymphocytic 59 anti botulism antibody 59 E2F Decoy 59 next generation URAT1 59 Exelixis compounds 59 leukemia ALL 59 Liprotamase 59 Aviptadil 59 oxybutynin ATD TM 59 YONDELIS R 59 TRANSDUR Sufentanil 59 PSN# [001] 59 glufosfamide 59 CG# [003] 59 Chemophase 59 AVE# 59 tanespimycin 59 Ambrisentan 59 candidate TNFerade biologic 59 Tiuxetan 59 Tanespimycin 59 refractory multiple myeloma 59 compound AEOL # 59 tesetaxel 59 Radezolid 59 PNT# 59 Fc fusion protein 59 AeroLEF TM 59 L BLP# 59 P#X# antagonist 59 ATL/TV# 59 velafermin 59 ARRY # 59 Onalta ™ 59 EndoTAG TM -1 59 mocetinostat 59 Kosan dependence 59 Cardio Vascu Grow 59 HCV polymerase inhibitors 59 vascular disrupting agents 59 DermaVir Patch 59 phase IIa 59 LEP ETU 59 CORT # 59 overactive bladder AA# 59 ISIS # 59 sapacitabine 59 II Clinical Trial 59 Tykerb lapatinib 59 Phase III Trial 59 p# biomarker 59 non metastatic osteosarcoma 59 rheumatoid arthritis psoriatic arthritis 59 OXIGON TM 59 TRACON Pharmaceuticals Inc. 59 Anticalin R 59 Vivecon 59 trabectedin 59 ASG 5ME 59 drug ISA# 59 Fodosine 59 Phase IIb trials 59 ASONEP 59 favorable pharmacokinetic profile 59 MyVax R 59 Aurexis 59 phase IIb 59 axitinib 59 ularitide 59 NP2 Enkephalin 59 rilonacept 59 romidepsin novel 59 thymalfasin 59 Amplimexon 59 OncoVEX 59 candidate AQ4N 59 SARMs 59 TRO# 59 trial evaluating PRX# 59 polymerase inhibitors 59 elacytarabine 59 HuMax CD4 59 OncoGel 59 Cintredekin Besudotox 59 therapeutic monoclonal antibody 59 ATL# [001] 59 tezampanel 59 oral anticancer 59 MTP inhibitor 59 antibody MAb 59 TMC# [002] 58 immune modulators 58 recombinant biopharmaceutical 58 Fleximer 58 Myelofibrosis 58 VNP#M 58 ALN PCS 58 anti CD3 monoclonal 58 BCR ABL inhibitor 58 GRNVAC1 58 Reverset 58 Nasdaq HALO 58 Onrigin 58 amrubicin 58 PEG Interferon lambda 58 HepDirect prodrug 58 Erbitux cetuximab 58 Tamibarotene 58 Prednisporin 58 #D#C# 58 histamine dihydrochloride 58 Aurora kinase 58 Dyloject TM 58 THR beta agonist 58 dependent kinase inhibitor 58 Metastatic Melanoma 58 MDV# 58 Inotek Pharmaceuticals Corporation 58 LEVADEX TM 58 Satraplatin 58 cisplatin gemcitabine 58 OvaRex R 58 trastuzumab Herceptin R 58 AVN# [001] 58 Cx# [002] 58 Trofex TM 58 HyperAcute 58 Tasimelteon 58 regorafenib 58 pomalidomide 58 incyclinide 58 MEK Inhibitor 58 Zemiva TM 58 Locked Nucleic Acid 58 systemic RNAi therapeutic 58 TELINTRA R 58 OHR/AVR# 58 chimeric monoclonal antibody 58 Allovectin 7 R 58 anticancer agent 58 systemic anaplastic large 58 immunomodulator 58 VALSTAR 58 Etoposide 58 clinical trials SGN 58 aldehyde dehydrogenase ALDH2 deficiency 58 EFAPROXYN 58 AVN# Phase 58 anticoagulant reversing agent 58 neratinib 58 XmAb# 58 RELOVAIR ™ 58 Herceptin trastuzumab 58 BrachySil 58 HepeX B 58 Lixisenatide 58 SAI EGF 58 DNA RNA Medicines 58 Nektar proprietary 58 FOLFOX6 chemotherapy regimen 58 torezolid phosphate 58 EDEMA3 58 VitiGam TM 58 DXL# 58 samalizumab 58 4SC AG ISIN DE# 58 candidates Azedra TM 58 Genasense oblimersen sodium Injection 58 Fibrillex TM 58 AEGR 58 M2 subunit 58 Achieves Primary Endpoint 58 Squalamine 58 CRTH2 58 MGCD# MGCD# [001] 58 Corlux 58 Romiplostim 58 Begins Dosing 58 Ceragenin ™ 58 romidepsin 58 pharmacokinetic PK study 58 Familial Adenomatous Polyposis FAP 58 novel emulsion formulation 58 Targretin 58 Raptiva ® 58 PF # [002] 58 LY# [003] 58 tafamidis 58 Oxytrex TM 58 cleavable linker 58 Tarceva erlotinib 58 selective modulator 58 SGLT Inhibitors 58 Lu AA# 58 confirmatory Phase III 58 ketolide antibiotic 58 SUTENT ® 58 novel histone deacetylase 58 Soliris eculizumab 58 immunotherapeutic vaccine 58 Davanat 58 cyclophilin inhibitors 58 SAR# [002] 58 torezolid 58 5 HT2A inverse 58 Litx 58 CML CP 58 mGluR2 NAM 58 phase 2a 58 glucokinase activator 58 Intravenous Human 58 induced macular edema 58 hormone refractory metastatic prostate 58 Azixa 58 integrase inhibitor 58 TRIOLEX TM HE# 58 Delafloxacin 58 XOMA 3AB 58 kidney urologic 58 XmAb ™ 58 Imprime PGG 58 phase Ib clinical 58 topically applied SEPA 58 novel topoisomerase 58 EVIZON TM squalamine lactate 58 lapatinib Tykerb 58 peptidic compound 58 NVA# 58 Maxy G# 58 Simulect 58 HuMax 58 obatoclax 58 HuMax EGFr 58 Abiraterone acetate 58 Trastuzumab 58 Solazed 58 PEGylated 58 Bicifadine 58 dacetuzumab 58 Pivotal Study 58 ISENTRESS raltegravir 58 Pivotal Phase III 58 potent topoisomerase II 58 renin inhibitors 58 injectable investigational 58 multitargeted 58 apoptosis inducer 58 Shigamabs ® 58 Spiegelmer ® 58 Dacetuzumab 58 randomized controlled Phase 58 ILUVIEN ® 58 ALN VSP 58 Ophena 58 dirucotide MBP# 58 adrenergic regulation 58 RANK Ligand inhibitor 58 JAK Inhibitor 58 trastuzumab emtansine T DM1 58 DB# [003] 58 MOR# 58 KSP inhibitor 58 RECOTHROM R 58 TÎ ² 4 58 Pharmion Corporation 58 selective androgen receptor modulators 58 ELND-#/AZD-# 58 JAK2 inhibitors 58 Proellex TM 58 sodium thiosulfate STS 58 MAP# 58 vidofludimus 58 metastatic renal cell carcinoma 58 tyrosine kinase inhibitor 58 acetonide FA 58 novel antifolate 58 SuperAntibody 58 IV APAP 58 epigenetic therapies 58 ADCC enhanced 58 ofatumumab HuMax CD# 58 HuMax TAC 58 sulfonylhydrazine class 58 GRN# 58 prokinetic agent 58 Phase III Pivotal 58 marketed pegylated interferons 58 catalytic antioxidant compounds 58 Acute myeloid leukemia AML 58 HspE7 58 Gemin X 58 Empatic TM 58 Phase IIb Clinical Trial 58 oral ridaforolimus 58 ON #.Na 58 ZYBRESTAT fosbretabulin 58 topical anti infective 58 assessing T DM1 58 humanized antibody 57 Phase #b/#a 57 motexafin gadolinium Injection 57 ixabepilone 57 myelofibrosis 57 Teflaro 57 Anidulafungin 57 lexidronam injection 57 LHRH receptor positive 57 Phase III Clinical Trials 57 Exherin TM 57 oral immunomodulatory 57 ara C 57 lumiliximab 57 topically administered 57 ALN TTR 57 candidates Azedra 57 Virulizin ® 57 PROVENGE ® 57 PRX # 57 lead molecular radiotherapeutic 57 Phase 1b trial 57 abiraterone acetate 57 Hsp# inhibitors 57 Pivotal Phase 57 drug conjugate 57 CCX# B 57 eltrombopag 57 Granulocyte Colony Stimulating Factor 57 interferon gamma 1b 57 Initiates Clinical Trial 57 JVRS 57 biliary tract cancer 57 lorvotuzumab mertansine 57 Tobira Therapeutics 57 Sunovion 57 octreotide implant 57 SCCHN 57 DEB# 57 JAK2 inhibitor 57 Alzhemed TM 57 Inhalation Solution 57 Lenocta 57 Phase III Clinical Trial 57 Zarnestra 57 Triolex 57 Golimumab 57 Phase 2a trial 57 Gleevec imatinib mesylate 57 visilizumab 57 Pemetrexed 57 ATL# [002] 57 panitumumab Vectibix 57 investigational compounds 57 Initiate Clinical Trial 57 R roscovitine CDK cyclin 57 budesonide foam 57 BioNumerik 57 lucinactant 57 Nasulin ™ 57 PHX# 57 Leuchemix 57 mGluR5 negative 57 intravesical infusion therapy 57 Uricase PEG 57 TKM ApoB 57 novel antiviral therapeutics 57 CINOD 57 Loramyc R 57 blinatumomab 57 investigational oral inhibitor 57 MET inhibitor 57 ruxolitinib 57 delta isoform 57 muscarinic receptor agonist 57 mda 7 57 talabostat 57 methylnaltrexone bromide 57 etanercept Enbrel 57 Yondelis ® 57 PEGylated anti 57 HuCNS SC ® 57 albiglutide 57 Telavancin 57 personalized immunotherapy 57 tumors GIST 57 BXT # 57 NOX E# 57 HCV protease 57 LHRH antagonists 57 Motesanib 57 Chrysalin 57 ZADAXIN ® 57 5 HT6 57 highly selective adenosine 57 Celator 57 TACI Ig 57 Anthracycline 57 Phase IIB 57 Crizotinib PF # 57 5 fluorouracil leucovorin 57 TLK# 57 Phase IIb clinical 57 INT# [002] 57 tumor vascular disrupting 57 TLR9 agonist 57 Actemra tocilizumab 57 nucleoside analogs 57 FUSILEV ® 57 MultiStat 57 teriflunomide 57 NEBIDO R 57 Junovan TM 57 ART# 57 novel orally administered 57 kinase inhibitor 57 Presents Preclinical 57 CRLX# 57 phase Ib 57 non alcoholic steatohepatitis 57 HCV NS5B polymerase 57 Ophena TM 57 Alinia 57 cilengitide 57 refractory NSCLC 57 Azacitidine 57 ARIKACE ™ 57 dyskinesia PD LID 57 Asentar 57 plus DOXIL 57 ZFP Therapeutics 57 dose escalation Phase 57 BiTE R 57 MGd